Josh Bilenker

Chief Executive Officer at Loxo Oncology at Lilly at Loxo Oncology, Inc.
Summary
Josh Bilenker is a distinguished professional with a diverse background in medicine, business, and leadership.
He pursued his medical education at The Johns Hopkins University School of Medicine, where he earned his MD degree, and also holds an AB in English from Princeton University.
Josh has held key roles in several reputable organizations, including serving as the Chief Executive Officer at Loxo Oncology at Lilly, where he plays a pivotal role in advancing healthcare and technology.
Prior to his current position, he was an Operating Partner at Aisling Capital, showcasing his proficiency in strategic decision-making and business operations.
With a wealth of experience, Josh Bilenker has previously served as the Chief Executive Officer at Loxo Oncology, highlighting his strong leadership skills and commitment to innovative healthcare solutions.
His tenure as a Medical Officer at the FDA reflects his expertise in regulatory matters and compliance within the healthcare industry.
Josh's foundation in medicine was further solidified during his time as a Resident and Fellow at the Hospital of the University of Pennsylvania, where he honed his clinical skills and knowledge.
His multidisciplinary background and extensive experience make him a valuable asset in the fields of oncology, pharmaceuticals, and healthcare innovation.